{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'TITLE PAGE', 'Protocol Title: A Randomized, Parallel, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety', 'and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis', 'Protocol Number: 235-9051-202', 'Amendment Number: 1', 'Product: TMB-001 (previously PAT-001) (Isotretinoin) Ointment (0.05% and 0.1%)', 'Short Title: A Vehicle-Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for', 'Treatment of Congenital Ichthyosis', 'Study Phase: 2b', 'Sponsor Name: Timber Pharmaceuticals, LLC', 'Legal Registered Address: 50 Tice Boulevard, Suite A26, Woodcliff Lake, NJ 07677', 'Investigational New Drug (IND) number: 122,058', 'Date of Protocol: 05 Aug 2020', '1']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Sponsor Signatory:', 'I have read this protocol in its entirety and agree to conduct the study accordingly:', 'Aum Tomald', 'Aug 5, 2020', 'Amir Tavakkol, PhD, Dip. Bact', 'Date', 'Chief Scientific Officer', \"The Medical Monitor's name and contact information can be found in Appendix 2.\", \"The Investigator's Agreement Page is provided in Appendix 8.\", '2']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'TABLE OF CONTENTS', 'TABLE OF CONTENTS', '3', 'TABLE OF TABLES', '6', '1.0', 'PROTOCOL SUMMARY', '7', '1.1', 'Synopsis', '7', '1.2', 'Schedule of Activities', '13', '2.0', 'INTRODUCTION', '16', '2.1', 'Study Rationale', '17', '2.2', 'Background', '17', '2.3', 'Benefit/Risk Assessment', '18', '3.0', 'OBJECTIVES AND ENDPOINTS', '20', '4.0', 'STUDY DESIGN', '22', '4.1', 'Overall Design', '22', '4.1.1', 'Treatment Groups', '22', '4.1.2', 'Treatment/Assessment Areas', '22', '4.2', 'Scientific Rationale for Study Design', '23', '4.3', 'Justification for Dose', '24', '4.4', 'End of Study Definition', '24', '5.0', 'STUDY POPULATION', '25', '5.1', 'Inclusion Criteria', '25', '5.2', 'Exclusion Criteria', '26', '5.3', 'Lifestyle Considerations', '27', '5.3.1', 'Meals and Dietary Restrictions', '27', '5.3.2', 'Activity', '27', '5.4', 'Screen Failures', '27', '6.0', 'STUDY TREATMENT', '29', '6.1', 'Study Treatment(s) Administered', '29', '6.2', ' Preparation/Handling/Storage/Accountability', '30', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '30', '6.4', 'Study Treatment Compliance', '31', '6.5', 'Concomitant Therapy', '31', '6.6', 'Dose Regimen Modification', '32', '6.7', 'Treatment after the End of the Study', '33', '3']\n\n###\n\n", "completion": "END"}